- Investing Ideas
- Swedish Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Swedish Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
2
1 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
2 companies
Vitrolife
Market Cap: SEK 12.3b
Provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas.
New
VITR
SEK 91.05
7D
0.1%
1Y
-34.4%
BioGaia
Market Cap: SEK 11.7b
A healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand.
BIOG B
SEK 115.90
7D
2.6%
1Y
18.1%